Immunotherapy in multiple myeloma: Current strategies and future prospects

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


Multiple myeloma is still a fatal disease. Despite advances in high-dose chemotherapy supported by autologous transplantations, relapse of the underlying disease remains the primary cause of treatment failure. Strategies for post-transplantation immunomodulation would be desirable for eradication of remaining tumor cells. Toward this end, immunotherapy aimed at inducing myeloma-specific immunity in patients has been exploited. Idiotype protein, secreted by myeloma cells, has been the main target for immunotherapy as it is the best-defined, tumor-specific antigen. The focus of this review article is the use of idiotype as a form of protein antigen to immunize patients, to load dendritic cells, or as part of DNA vaccines. Various strategies of immunotherapy and the outcome of clinical trials are also discussed.

Original languageEnglish (US)
Pages (from-to)391-398
Number of pages8
JournalExpert Review of Vaccines
Issue number3
StatePublished - Jun 1 2003


  • Dedritic cells
  • Idiotype
  • Immunotherapy
  • Multiple myeloma
  • T-cells

ASJC Scopus subject areas

  • Immunology
  • Molecular Medicine
  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Immunotherapy in multiple myeloma: Current strategies and future prospects'. Together they form a unique fingerprint.

Cite this